All In Biotech

Free tool

FAERS Monitor: Viltepso

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 212154 or its brand name (Viltepso, Viltolarsen). Reports on generic versions are filed under their own applications.

Reports

170

Serious

54

32% of reports

Hospitalization

42

Death reported

7

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pyrexia21
  • vomiting14
  • illness11
  • weight increased9
  • pneumonia8
  • malaise7
  • cough6
  • covid-196
  • product dose omission issue6
  • diarrhoea5
  • fall5
  • influenza5
  • off label use5
  • sars-cov-2 test positive5
  • abdominal discomfort4

Reports by year received

View as table
YearReports
20201
202113
202219
202329
202441
202547
202620

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,989 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
sars-cov-2 test positiveSignal546.919.8181
illnessSignal1113.27.5113
pyrexiaSignal217.55.0114
influenzaSignal55.52.314
weight increasedSignal95.02.625
covid-19Signal64.21.912
vomitingSignal143.72.225
pneumoniaSignal83.11.69
abdominal discomfort43.01.13
coughSignal62.61.25
product dose omission issueSignal62.51.24
malaise72.01.03
fall51.90.81
diarrhoea51.00.40
off label use50.70.30

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.